The trial presented by Dr Rik van Severen van University Hospitals Leuven investigates the efficacy and safety of alpelisib in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. PIK3CA mutations

In this retrospective analysis of TNBC patients undergoing adjuvant chemotherapy between 2000 and 2017 presented by Dr Kristien Borremans from University Hospitals Leuven , the study aimed to assess the

This initiative presented by Dr Josephine Van Cauwenberge van University Hospitals Leuven aims to establish genomic risk scores for a specific cohort of clinically low-risk patients who did not undergo

Dr Glen Vergauwen from Ghent University Hospital introduces the GRACE trial, a randomized controlled clinical trial targeting breast cancer patients experiencing vaginal atrophy during endocrine therapy. The study aims to

The microbiome study presented by Dr Nynke Willers from University Hospitals Leuven investigates the impact of breast cancer therapy on the vaginal microbiome and its associated sexual implications. Premenopausal breast

Prof Hans-Christian Kolberg from Marienhospital Bottrop in Germany is presenting EUBREAST-03, part of the AXSANA trial. This trial constitutes a consortium of breast cancer centres aimed at assessing the surgical

Professor Patrick Neven presents an investigation examining the correlation between parity, age at the first full-term pregnancy (FTP1), and the age of BC diagnosis, as well as the prevalence of

The MonarchE study led to the reimbursement of the CDK4/6 inhibitor abemaciclib in Belgium for high-risk ER+/HER2- breast cancer patients in the adjuvant setting for a 2-year period. To assess

The second most common subtype of breast cancer, ILC, was investigated using spatial RNA sequencing ST to better understand its biology. Dr Matteo Serra from the institut Jules Bordet in

Dr Karen Van Baelen from University Hospitals Leuven presents research by Dr. Bauters on CDK4/6 inhibition in metastatic breast cancer patients. The study compared patients with ILC and NST receiving

Dr Luca Malorni, a medical oncologist and Director of the Translational Research Unit at the Hospital of Prato, Italy presented at SABCS 2023 the relation between serum thymidine kinase activity

Prof Nuhad Ibrahim, medical oncologist at the Department of Breast Medical Oncology at MD Anderson Cancer Center in Houston, presented at SABCS 2023 the results of the ELEKTRA Phase 1b

In this poster from SABCS 2023, Prof Antonio Llombart, Head of department of Medical Oncology at the University Hospital Arnau de Vilanova in Valencia, presents the DESTINY-Breast15 study. This study

In this poster from SABCS 2023, Kaat Van Herck, master student at the University Hospitals, Leuven, presented her master’s thesis on conventional imaging in early-stage invasive lobular breast cancer.
Invasive

In this poster, Dr Karen Van Baelen, a Researcher PhD student at the University Hospitals Leuven in Belgium, presented results from the post-mortem tissue donation program UPTIDER on the metastatic

In this poster, Dr Guilherme Nader Marta, medical oncologist at the Dana Farber Cancer Institute in Boston, US, presented the prognostic and predictive values of HER2-low in early breast cancer

In this poster, Prof Christine Desmedt, Head of the Laboratory for Translational Breast Cancer Research at the University Hospitals Leuven in Belgium, aimed to investigate which biological characteristics are associated

Prof Sara Hurvitz, medical oncologist and clinical research leader at Fred Hutchinson Cancer Center in Seattle, briefly discusses with Prof François Duhoux, medical oncologist and head of clinic of the

Dr Agostinetto reports whether concomitant use of PPIs could have affected clinical outcomes in patients treated with palbociclib in PALLAS. The PALLAS study randomised 5796 patients to receive either 2